INMAGENE BIOPHARMACEUTICALS
It is a leading biotech company focused on immunology-related therapeutic areas.
INMAGENE BIOPHARMACEUTICALS
Social Links:
Industry:
Biopharma Biotechnology Health Care
Address:
Pudong, Shandong, China
Country:
China
Website Url:
http://www.inmagenebio.com
Total Employee:
51+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
121 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS HiChina DNS
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Current Employees Featured
Founder
Investors List
Kunlun Fund
Kunlun Fund investment in Series C - Inmagene Biopharmaceuticals
HT Capital
HT Capital investment in Series C - Inmagene Biopharmaceuticals
Panacea Venture
Panacea Venture investment in Series C - Inmagene Biopharmaceuticals
TriWise Capital
TriWise Capital investment in Series C - Inmagene Biopharmaceuticals
VMS Asset Management
VMS Asset Management investment in Series C - Inmagene Biopharmaceuticals
South China Venture Capital
South China Venture Capital investment in Series C - Inmagene Biopharmaceuticals
Highlight Capital
Highlight Capital investment in Series C - Inmagene Biopharmaceuticals
Kunlun Capital
Kunlun Capital investment in Series B - Inmagene Biopharmaceuticals
South China Venture Capital
South China Venture Capital investment in Series B - Inmagene Biopharmaceuticals
Vertex Ventures China
Vertex Ventures China investment in Series B - Inmagene Biopharmaceuticals
Official Site Inspections
http://www.inmagenebio.com Semrush global rank: 5.85 M Semrush visits lastest month: 1.42 K
- Host name: inmagene.tempurl.host
- IP address: 104.156.230.209
- Location: San Jose United States
- Latitude: 37.3387
- Longitude: -121.8914
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 95113
More informations about "Inmagene Biopharmaceuticals"
Ushering in a new era of therapies for immunological …
To learn more about our science, pipeline, clinical trials, and investment opportunities or if you have other inquiries, please email us at [email protected]. Inmagene Global Headquarters 12526 High Bluff …See details»
Inmagene Biopharmaceuticals - Crunchbase Company …
Contact Email [email protected] Diseases do not recognize borders; why should drug innovation? We are a team of scientists and physicians driven by a shared commitment: to fulfill unmet medical needs for patients worldwide by …See details»
Inmagene Company Profile 2024: Valuation, Funding & Investors
Www.inmagenebio.com. Ownership Status. Privately Held (backing) Financing Status. Venture Capital-Backed. Corporate Office. 12526 High Bluff Drive; Suite 345; San Diego, CA 92130; …See details»
Inmagene Biopharmaceuticals Company Profile | Management …
[email protected]: Inmagene Biopharmaceuticals Top Competitors. Company Employees Revenue Top technologies; Harbour BioMed. 177: $89.5 M: Avaxia Biologics. 27: $6.3 M: …See details»
Inmagene Biopharmaceuticals - LinkedIn
Https://inmagenebio.com 73 1 Comment Like Comment Share Inmagene Biopharmaceuticals 1,863 followers 6mo Report this post Inmagene, developing a unique clinical-stage non-depleting anti-OX40 mAb ...See details»
Inmagene Biopharmaceuticals - Overview, News & Similar
May 5, 2024 Inmagene announces formation of Celexor Bio based on its anti-ILT7 mAb with enhanced pDC depletion function SAN DIEGO, Sept. 21, 2023 /PRNewswire/ -- Inmagene …See details»
Inmagene Biopharmaceuticals - Craft
Inmagene Biopharmaceuticals is a company that produces medicines focused on immunology-related therapeutic areas. It operates the scientific trials multi-center that conducts research …See details»
Inmagene Biopharmaceuticals - Company Profile & Staff Directory ...
Inmagene is a global clinical-stage biotechnology company focused on developing novel therapeutics for immunology-related diseases. Inmagene’s most advanced drug candidate is …See details»
Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd.
IMG-007 is a novel anti-OX40 monoclonal antibody (mAb) engineered for potentially once every 12 weeks dosing and an improved safety profile IMG-007 is being evaluated for the treatment …See details»
PARTNERSHIPS - Inmagene Bio
To expedite the development of IMG-018, an in-house discovered asset via our proprietary QuadraTek® platform, Inmagene has partnered with Aditum Bio to establish Celexor Bio, a …See details»
Pioneering a new generation of therapies for …
We are pioneering a new generation of therapies with best-in-class potential across a spectrum of immunological and inflammatory diseases. Leveraging external innovation and our proprietary QuadraTek® platform, we are …See details»
Yingmai Chuangxiang Biomedical (Wuhan) Co., Ltd.
SAN DIEGO, SHANGHAI and HONG KONG, Aug. 9, 2022 /PRNewswire/ -- Inmagene Biopharmaceutical ("Inmagene") and HUTCHMED (China) Limited ("HUTCHMED") …See details»
Jonathan Wang - Inmagene Biopharmaceuticals | LinkedIn
Jonathan Wang is the Founder, Chairman and CEO of Inmagene, a global clinical-stage… · Experience: Inmagene Biopharmaceuticals · Education: Stanford University Graduate School …See details»
Chi-Med and Inmagene Announce Strategic Partnership to
Organization. We believe that these four candidates have scope in multiple immunological diseases and we are pleased to see these opportunities investigated further by Inmagene.” …See details»
Chi-Med and Inmagene Announce Strategic Partnership to …
Jan 11, 2021 HONG KONG, SHANGHAI, China, SAN DIEGO & FLORHAM PARK, N.J., Jan. 10, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) …See details»
Inmagene announces formation of Celexor Bio based on its anti …
Sep 21, 2023 Further information is available at www.inmagenebio.com. About Aditum Bio Aditum Bio is committed to improving public health by accelerating R&D in disease areas with …See details»
Chi-Med and Inmagene announce strategic partnership to …
Hong Kong, Shanghai, San Diego & Florham Park, NJ: Monday, January 11, 2021 — Inmagene Biopharmaceuticals (“Inmagene”) and Hutchison China MediTech Limited (“Chi-Med”) …See details»
Chi-Med and Inmagene Announce Strategic Partnership to
HONG KONG, SHANGHAI, China, SAN DIEGO & FLORHAM PARK, N.J., Jan. 10, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“ Chi-Med ”) (Nasdaq/AIM: HCM) and …See details»
News and Publications about our pipeline | Inmagene Bio
Oct 9, 2024 Access research publications, research, and other media about Inmagene Bio and our pipelineSee details»
See our therapeutic pipeline and learn about our QuadraTek® …
The first clinical-stage nondepleting anti-OX40 monoclonal antibody (mAb) IMG-007 is an IgG1 mAb targeting OX40, a costimulatory receptor that presents primarily on activated T cells. 1 …See details»